NASDAQ : ANNX
Annexon, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 4.05 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 767.80M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 767.80M |
| Enterprise Value | 583.20M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 189.58M |
| Shares Outstanding | 189.58M |
| Shares Change (YoY) | +21.24% |
| Shares Change (QoQ) | +3.50% |
| Owned by Insiders (%) | 0.92% |
| Owned by Institutions (%) | 90.08% |
| Float | 163.76M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 84.44 |
| PB Ratio | 3.80 |
| P/TBV Ratio | 4.13 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 5.53 |
| Quick Ratio | 5.44 |
| Debt / Equity | 0.13 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -105.26% |
| Return on Assets (ROA) | -51.54% |
| Return on Invested Capital (ROIC) | -60.18% |
| Return on Capital Employed (ROCE) | -101.43% |
| Weighted Average Cost of Capital (WACC) | 11.19% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.20M |
| Employee Count | 92 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.33 |
| 52-Week Price Change | +26.96% |
| 50-Day Moving Average | 4.20 |
| 200-Day Moving Average | 5.22 |
| Relative Strength Index (RSI) | 52.42 |
| Average Volume (20 Days) | 3,543,199 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 31.63M |
| Short Previous Month | 32.01M |
| Short % of Shares Out | 16.68% |
| Short % of Float | 19.31% |
| Short Ratio (days to cover) | 9.44 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -210.56M |
| Pretax Income | -202.67M |
| Net Income | -202.67M |
| EBITDA | -208.39M |
| EBIT | -210.56M |
| Earnings Per Share (EPS) | -$1.13 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 209.24M |
| Total Debt | 24.65M |
| Net Cash | 184.59M |
| Net Cash Per Share | $0.97 |
| Equity (Book Value) | 186.06M |
| Book Value Per Share | 1.07 |
| Working Capital | 174.28M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -193.03M |
| Capital Expenditures | -185,000 |
| Depreciation & Amortization | 2.17M |
| Net Borrowing | n/a |
| Free Cash Flow | -193.22M |
| FCF Per Share | -$1.02 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -21.24% |
| Shareholder Yield | -21.24% |
| Earnings Yield | -27.83% |
| FCF Yield | -25.17% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $17.00 |
| Price Target Difference | 319.75% |
| Analyst Consensus | Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |